Med BioGene Loss Declines in Advance of US Launch for LungExpress Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics firm Med BioGene today reported that its first-quarter net loss increased around 6 percent as it continued to prepare to launch its LungExpress Dx test.

The Vancouver, BC-based firm reported no revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: comprehensive analysis of somatic mutations in breast cancer, and more.

A number of studies indicate that genes might influence political beliefs, Scientific American Mind reports.

Craig Venter's Human Longevity is deeply phenotyping individuals and capturing their genetic profiles to explore aging.

The San Francisco Business Times examines Verily's latest hires.